Synairgen (#SNG) – dosing of inhaled interferon beta formulation commenced
- 2021-02-15 07:27:24
From the FCA's spreadsheet of short positions required to be disclosed to it, the following shows the shorted AIM shares with positions from 2019, 2020 and thus far in 2021 (by net short position %, those in bold not on the list at the start of 2021) – and if this position has increased (red), reduced (green) or remained unchanged (black) since last week...
Is it just me or is the rest of the world moving incredibly quickly while I put up with the second lockdown. Or as I refer to it “mockdown” – with my children still going to school and interacting with half the local villages and towns. Not only does The Donald win / lose / win??? again (if one accepts some the US news feeds), we now have a vaccine for Covid. Apparently. I’m sure the infrastructure to distribute and store a product that requires -80 degrees is well within the capabilities of our fearsome leaders to sort – after all distributing and storing PPE (like masks) is far more difficult and they did that without any problem I recall. So where does that leave me in my thinking for Synairgen (SNG)?
Without question the 2020 investment world will be noted for a big market crash and regain in Q1/Q2, and Covid19 related stock gains. I’m sure a few millionaires have been created, and few will lose much of the gain in months to come- such is the investment world. I have commented on Synairgen (SNG) previously as the single case in the Covid19 investment space I was comfortable with. I was waiting for yesterday’s placing news.
I wrote about Synairgen (SNG) back in July, and in doing so earned the dubious ticker from Tom Winnifrith as a “ramper” and the honour of a Special Bearcast as a response. The ticker amused me greater and I freely admit I agreed with 95% of Tom’s commentary on how to value a drugs company. However I see a “special situation” with this company’s SNG001 potential Covid treatment that may break the normal valuation rule set.
Synairgen (SYN) came onto my radar earlier this year. I bought. After yesterday’s monumental rise I’m quids in, and remain a holder. But I owe an apology – I dropped it from my final buy tip selection recorded for last weekend’s Mineprophets show. As discussed with Tom Winnifrith, I did not consider myself sufficiently expert to tip mining shares. Synairgen is a drug company, which is also not my area of expertise, however I liked the investment case but could not tip it – what do I know about bio-meds? Perhaps I should be bolder and more confident?